Weight loss drug + exercise: a Muscle-Saving combo?

NCT ID NCT07091500

Recruiting now Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study looks at whether adding exercise to a common weight-loss drug (semaglutide) can prevent muscle loss and keep people physically strong. Researchers will follow 40 adults with obesity for two years, tracking muscle mass, strength, and function. They will also see what happens when people stop taking the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Semaglutide (a GLP-1 receptor agonist) and exercise training
What this could lead to: If successful, this could show that combining exercise with GLP-1 drugs helps maintain muscle and physical function during weight loss, and inform better long-term strategies.
What could go wrong: This is a small, early-phase study with only 40 participants, so results may not apply broadly. The impact of stopping treatment is uncertain, and exercise adherence may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN CONNECTIVITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder skeletal muscle disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN CONNECTIVITY OBESITY SKELETAL MUSCLE

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.